ABC/DTG/3TC immediate release tablets — Competitive Intelligence Brief

ABC/DTG/3TC immediate release tablets (ABC/DTG/3TC immediate release tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NRTI + INSTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (NRTI + INSTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule

Target snapshot

ABC/DTG/3TC immediate release tablets (ABC/DTG/3TC immediate release tablets) — ViiV Healthcare. A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABC/DTG/3TC immediate release tablets TARGET	ABC/DTG/3TC immediate release tablets	ViiV Healthcare	phase 3	Antiretroviral combination (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
tenofovir, lamivudine, efavirenz	tenofovir, lamivudine, efavirenz	Bamrasnaradura Infectious Diseases Institute	marketed	Antiretroviral combination therapy (NRTI/NtRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
efavirenz + emtricitabina + tenofovir	efavirenz + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NRTI + INSTI) class)

1. ViiV Healthcare · 2 drugs in this class